Home Tags M&A
See the first look at Octavia Spencer playing a knife-wielding, teen-terrorizing villain the in the trailer for "Ma," a psychological horror-thriller.
A CEO at one of the world’s largest asset managers is downbeat on European M&A while ‘people are frozen’ before Brexit
Europe's economic malaise has had a real impact on investment and deal-making, says the CEO of asset manager Lazard. Brexit is a key concern.
Spotify reportedly plans to buy Gimlet Media for more than $200 million in big expansion into podcasting
Spotify plans to pay more than $200 million to buy Gimlet Media, Recode reported, saying the company wants to expend into the booming podcasting area.
Deutsche Bank’s stock is getting hit. Again. This time it’s because of weaker than expected earnings.
Deutsche Bank fell 2% after the bank reported earnings. The shares have had a rollercoaster ride lately, and have plunged 48% in the past year.
The CEO behind Bustle and the new Gawker is reportedly making a bid on the remaining Gizmodo Media blogs
Bryan Goldberg bought the defunct Gawker.com for $1.35 million in July
Nasdaq says the shutdown is paralyzing the IPO market — and the huge bottleneck of firms waiting to go public is getting worse
Speaking at Davos, Nelson Griggs said the shutdown meant the SEC couldn't process the paperwork required for companies looking to go public.
Barclays says talk of any Deutsche Bank merger is a red flag for earnings — and the UK bank is slashing its price targets
"Profitability may have deteriorated further in the fourth quarter, and the current strategy/targets are looking less and less viable," Barclays said.
Switzerland’s Veeam Software just scooped up half a billion dollars in funding and the cofounder says he’s ready to start buying companies...
Veeam Software just closed $500 million from Insight Venture Partners, and it's currently looking into small companies to acquire later this year.
We’ll get you caught up on all the news you missed at the year’s biggest healthcare investor conference
Among the highlights: an $8 billion deal (and more to come?), a promising depression drug, and a strategy deep dive from a healthcare giant.
Bristol-Myers Squibb is acquiring Celgene, the drugmakers announced Thursday in a deal valued at $74 billion.